glp-1 agonist review Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH glp 1 agonist risks GLP-1
Description
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
Explore Fridays' weight loss program pricing model
Stratified analyses showed no differences between subgroups
In late April 2025, the FDA issued a key update regarding the use of compounded GLP-1 receptor agonists like semaglutide and tirzepatide
No compounding
The best part
